Advanced

The concept of treatment-free remission in chronic myeloid leukemia

Saußele, S.; Richter, J. LU ; Hochhaus, A. and Mahon, F. X. (2016) In Leukemia 30(8). p.1638-1647
Abstract

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has been stopped successfully in approximately half of the patients with deep molecular response. This has prompted the development of a new concept in the evaluation of CML patients known as 'treatment-free remission'. The future in CML treatment will be to define criteria for the safe and most promising discontinuation of TKI on one hand, and, on the other, to increase the number of patients available for such an attempt. Until safe criteria... (More)

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has been stopped successfully in approximately half of the patients with deep molecular response. This has prompted the development of a new concept in the evaluation of CML patients known as 'treatment-free remission'. The future in CML treatment will be to define criteria for the safe and most promising discontinuation of TKI on one hand, and, on the other, to increase the number of patients available for such an attempt. Until safe criteria have been defined, discontinuation of therapy is still experimental and should be restricted to clinical trials or registries. This review will provide an overview of current knowledge as well as an outlook on future challenges.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
30
issue
8
pages
10 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:84973176467
ISSN
0887-6924
DOI
10.1038/leu.2016.115
language
English
LU publication?
no
id
f89850ea-d0ef-4d58-b11b-10c771182039
date added to LUP
2016-12-30 12:56:04
date last changed
2017-11-19 04:36:26
@article{f89850ea-d0ef-4d58-b11b-10c771182039,
  abstract     = {<p>The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has been stopped successfully in approximately half of the patients with deep molecular response. This has prompted the development of a new concept in the evaluation of CML patients known as 'treatment-free remission'. The future in CML treatment will be to define criteria for the safe and most promising discontinuation of TKI on one hand, and, on the other, to increase the number of patients available for such an attempt. Until safe criteria have been defined, discontinuation of therapy is still experimental and should be restricted to clinical trials or registries. This review will provide an overview of current knowledge as well as an outlook on future challenges.</p>},
  author       = {Saußele, S. and Richter, J. and Hochhaus, A. and Mahon, F. X.},
  issn         = {0887-6924},
  language     = {eng},
  month        = {08},
  number       = {8},
  pages        = {1638--1647},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {The concept of treatment-free remission in chronic myeloid leukemia},
  url          = {http://dx.doi.org/10.1038/leu.2016.115},
  volume       = {30},
  year         = {2016},
}